The estimated Net Worth of Mark S Forman is at least $47 Tisíc dollars as of 31 December 2023. Dr Forman owns over 50,000 units of Passage Bio Inc stock worth over $47,033 and over the last 3 years he sold PASG stock worth over $0.
Dr has made over 2 trades of the Passage Bio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of PASG stock worth $38,500 on 31 December 2023.
The largest trade he's ever made was exercising 50,000 units of Passage Bio Inc stock on 31 December 2023 worth over $38,500. On average, Dr trades about 7,857 units every 124 days since 2021. As of 31 December 2023 he still owns at least 61,082 units of Passage Bio Inc stock.
You can see the complete history of Dr Forman stock trades at the bottom of the page.
Dr. Mark Forman M.D., Ph.D. is the Chief Medical Officer at Passage Bio Inc.
Dr D is 57, he's been the Chief Medical Officer of Passage Bio Inc since . There are 3 older and 5 younger executives at Passage Bio Inc. The oldest executive at Passage Bio Inc is Dr. James M. Wilson M.D., Ph.D., 66, who is the Co-Founder & Chief Scientific Advisor.
Mark's mailing address filed with the SEC is ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA, PA, 19103.
Over the last 5 years, insiders at Passage Bio Inc have traded over $535,533 worth of Passage Bio Inc stock and bought 4,392,148 units worth $41,339,284 . The most active insiders traders include Liam Ratcliffe, Advisors Llc Orbi Med Capit... a Thomas Woiwode. On average, Passage Bio Inc executives and independent directors trade stock every 37 days with the average trade being worth of $92,858. The most recent stock trade was executed by Kathleen Borthwick on 10 February 2024, trading 4,000 units of PASG stock currently worth $3,080.
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
Passage Bio Inc executives and other stock owners filed with the SEC include: